This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by O’Rullian, J. J Articles by Williams, D. R Search for Related Content PubMed PubMed Citation Articles by O’Rullian, J. J Articles by Williams, D. R Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CEFAZOLIN Social Bookmarking                         What's this?

The effects of haemofiltration on cefazolin levels during cardiopulmonary bypass

College of Medicine, Pennsylvania State University, Hershey, Pennsylvania

Robert K Wise

College of Medicine, Pennsylvania State University, Hershey, Pennsylvania

Robert M McCoach

College of Medicine, Pennsylvania State University, Hershey, Pennsylvania

Charles P Kingsley

College of Medicine, Pennsylvania State University, Hershey, Pennsylvania

Dennis R Williams

College of Medicine, Pennsylvania State University, Hershey, Pennsylvania

Ultrafiltration has been shown to affect cardiac drug concentrations during cardiopulmonary bypass (CPB), based on their respective pharmacological properties. In an attempt to understand the aetiology of sternal wound infections, a study was performed to eliminate the use of ultrafiltration as a possible cause. We compared cefazolin levels at three time intervals during the course of routine CPB with ultrafiltration to those levels in a control group in which ultrafiltration was not used. Our results indicate that there is little difference in the rate of decay of antibiotic levels with or without the use of a haemoconcentrator. This implies that ultrafiltration procedures do not put the patient at any increased risk for infection and that additional measures beyond that which we would normally use at our institution need not be taken.

Perfusion, Vol. 13, No. 3, 176-180 (1998)
DOI: 10.1177/026765919801300304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-J. Lehot Cefazolin prophylaxis during cardiac operations Ann. Thorac. Surg., February 1, 2004; 77(2): 755 - 756. [Full Text] [PDF]